Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 59

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 59
---
disability”, then:

| • |     | With respect to Mr. Segal, he would have been entitled to (1) continued participation in our group insurance plans and employee benefits for 12 months; and (2) accelerated vesting of his options that were subject to time-based vesting schedule that were scheduled to vest in the 12 months following the date of termination, and his vested options would have remained exercisable for up to 12 months following such termination. |

| • |     | Dr. Koehler would have been, and Dr. Zinda would be, entitled to (1) payment of COBRA premiums for up to seven months and (2) accelerated vesting of the executive officer’s options that are subject to time-based vesting schedule that were scheduled to vest in the 12 months following the date of termination, and the executive officer’s vested options (other than options qualifying as incentive stock options) would remain exercisable for up to 12 months following the date of such termination. |

If we were to elect to enforce the non-competitionprovisions set forth in Dr. Koehler’s or Dr. Zinda’s employment agreement following an involuntary termination by us for “just cause” (as such term is defined in the respective agreement) or such executive officer’s resignation, then we have agreed to provide the executive officer with consideration in the form of the greater of (x) continuing salary payments for one year following the date of the executive officer’s termination at a rate equal to no less than 50% of the highest annualized base salary paid to the executive officer by us within the two years prior to the executive’s termination date and (y) accelerated vesting of all of the executive officer’s options subject to a time-based vesting schedule which would have vested if the executive officer had remained employed for an additional 12 months following the termination date. Equity Compensation Plan Information The following table summarizes our equity compensation plan information as of December 31, 2024.

| Plan Category                                             |     | Number of     
 Securities to 
 be Issued     
 Upon          
 Exercise of   
 Outstanding   
 Options,      
 RSUs,         
 Warrants      
 and Rights(1) 
 (#)           |            |     | Weighted      
 Average       
 Exercise      
 Price of      
 Outstanding   
 Options,      
 Warrants      
 and Rights(2) 
 ($)           |       |     | Number of      
 Securities     
 Remaining      
 Available for  
 Future         
 Issuance       
 Under Equity   
 Compensation   
 Plans          
 (Excluding     
 Securities